HeartMate II与HeartWare左心室辅助装置相关卒中与颅内出血的系统综述
该系统综述检索2007年1月至2016年6月PubMed英文文献,纳入48篇文献共11,310例HeartMate II(HMII)和HeartWare左心室辅助装置患者。总体缺血性卒中或颅内出血发生率为9.8%(1110例),0.08事件/患者年。HMII患者缺血性卒中中位发生率6.0%(0.06事件/患者年),HeartWare为7.5%(0.09事件/患者年);HMII颅内出血中位发生率3.0%(0.04事件/患者年),HeartWare为8.0%(0.08事件/患者年)。左心室辅助装置相关缺血性卒中中位死亡率为31%(HMII 33%,HeartWare 11.5%),颅内出血后中位死亡率为71%(HMII 75%,HeartWare 44%)。作者认为事件率异质性大,鉴于高死亡率,需进一步前瞻性研究。
要点
- 总体缺血性卒中或颅内出血发生率为9.8%(1110例),0.08事件/患者年,设备支持中位时长112天。
- HMII患者缺血性卒中中位发生率6.0%(0.06事件/患者年),HeartWare为7.5%(0.09事件/患者年)。
- HMII患者颅内出血中位发生率3.0%(0.04事件/患者年),HeartWare为8.0%(0.08事件/患者年)。
- 左心室辅助装置相关缺血性卒中中位死亡率为31%(HMII 33%,HeartWare 11.5%)。
- 颅内出血后中位死亡率为71%(HMII 75%,HeartWare 44%)。
适用人群与场景
- 纳入2007年1月至2016年6月PubMed英文文献中涉及HeartMate II和HeartWare左心室辅助装置的患者,共48篇文献、11,310例患者。
- 设备支持中位时长112天,总患者年13,723。
研究设计与关键结果
- 系统综述纳入48篇文献共11,310例患者(33篇HMII、6篇HeartWare、8篇两者、1篇未指明设备)。
- 总体缺血性卒中或颅内出血发生于9.8%(1110例),0.08事件/患者年。
- 缺血性卒中:HMII中位6.0%或0.06事件/患者年(范围0-16%或0-0.21事件/患者年) vs HeartWare中位7.5%或0.09事件/患者年(范围4-17.1%或0.01-0.94事件/患者年)。
- 颅内出血:HMII中位3.0%或0.04事件/患者年(范围0-13.5%或0-0.13事件/患者年) vs HeartWare中位8.0%或0.08事件/患者年(范围3-23%或0.01-0.56事件/患者年)。
- 左心室辅助装置相关缺血性卒中中位死亡率31%(HMII 33%,范围2.4-75%;HeartWare 11.5%,范围3.9-40%)。
- 颅内出血后中位死亡率71%(HMII 75%,范围3.9-100%;HeartWare 44%,范围3.1-88%)。
证据类型、等级与局限
- 证据类型:系统综述。
- 局限:原文报告事件率异质性大,并指出需进一步前瞻性研究。
对床旁实践的改变
- 作者认为左心室辅助装置置入后缺血性卒中与颅内出血常见且死亡率高,需进一步前瞻性研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Ischemic stroke and intracranial hemorrhage (ICH) following left ventricular assist device (LVAD) placement are major causes of morbidity. The incidence and mortality associated with these events stratified by device type have not been systematically explored.
METHODS: A systematic review of PubMed was conducted from January 2007 through June 2016 for all English-language articles involving HeartMate II (HMII) and HeartWare LVAD patients. Ischemic stroke and/or ICH incidence (events per patient-year) and associated mortality rates were abstracted for each device type.
RESULTS: Of 735 articles reviewed, 48 (11,310 patients) met inclusion criteria (33 HMII, six HeartWare, eight both devices, and one unspecified). The median duration of device support was 112 days (total 13,723 patient-years). Overall, ischemic stroke or ICH occurred in 9.8% (1110 persons and 0.08 events per patient year [EPPY]). Ischemic stroke occurred in a median of 6.0% or 0.06 EPPY (range 0-16% or 0-0.21 EPPY) of HMII patients versus 7.5% or 0.09 EPPY (range 4-17.1% or 0.01-0.94 EPPY) of HeartWare patients. ICH occurred in a median of 3.0% or 0.04 EPPY (range 0-13.5% or 0-0.13 EPPY) of HMII and 8.0% or 0.08 EPPY (range 3-23% or 0.01-0.56 EPPY) of HeartWare patients. The median mortality rate for LVAD-associated ischemic stroke was 31% (HMII: 33%, [range 2.4-75%] and HeartWare: 11.5% [range 3.9-40%]), and the median mortality rate following ICH was 71% (HMII: 75%, [range 3.9-100%] and HeartWare: 44%, [range 3.1-88%]).
CONCLUSIONS: Ischemic stroke and ICH are common after LVAD placement, but heterogeneous event rates are reported in the literature. Given the high associated mortality, further prospective study is warranted.
参考来源
- Cho SM, Moazami N, Frontera JA, et al. Stroke and Intracranial Hemorrhage in HeartMate II and HeartWare Left Ventricular Assist Devices: A Systematic Review. Neurocrit Care. 2017. PMID: 28324260. doi:10.1007/s12028-017-0386-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。